Owing to the undesirable effects of COX-2-selective inhibitors (thrombotic events, hypertension, and heart failure), interest was focused on mPGES-1 as an alternative target for the development of analgesics and anti-inflammatory drugs [12]. This evidence concerns the gene PTGER2 and Hypertension.